| 2020 |
| 03/17 | 2,011 | 2,190 | 2,002 | 2,132 | +2.9% | 218,800 | 1104億6144万 | -19.61% |
| 03/16 | 2,139 | 2,172 | 2,069 | 2,072 | -2.4% | 107,900 | 1073億5277万 | -23% |
| 03/13 | 2,165 | 2,214 | 2,044 | 2,123 | -6.27% | 174,400 | 1099億9514万 | -22.29% |
| 03/12 | 2,322 | 2,337 | 2,259 | 2,265 | -4.11% | 124,200 | 1173億5233万 | -18.2% |
| 03/11 | 2,397 | 2,430 | 2,362 | 2,362 | -3.32% | 113,000 | 1223億7801万 | -15.61% |
| 03/10 | 2,424 | 2,556 | 2,308 | 2,443 | +0.33% | 97,100 | 1265億7472万 | -13.49% |
| 03/09 | 2,526 | 2,526 | 2,423 | 2,435 | -5.47% | 97,500 | 1261億6023万 | -14.59% |
| 03/06 | 2,622 | 2,624 | 2,566 | 2,576 | -3.45% | 87,500 | 1334億6561万 | -10.46% |
| 03/05 | 2,686 | 2,714 | 2,664 | 2,668 | +1.21% | 103,100 | 1382億3224万 | -7.9% |
| 03/04 | 2,631 | 2,693 | 2,629 | 2,636 | -1.68% | 81,000 | 1365億7428万 | -9.48% |
| 03/03 | 2,765 | 2,769 | 2,668 | 2,681 | -1.36% | 146,600 | 1389億578万 | -8.47% |
| 03/02 | 2,614 | 2,732 | 2,607 | 2,718 | +3.94% | 169,200 | 1408億2280万 | -7.71% |
| 02/28 | 2,661 | 2,687 | 2,593 | 2,615 | -3.54% | 125,000 | 1354億8624万 | -11.69% |
| 02/27 | 2,743 | 2,744 | 2,708 | 2,711 | -1.81% | 119,100 | 1404億6012万 | -9.06% |
| 02/26 | 2,734 | 2,772 | 2,707 | 2,761 | -0.07% | 116,400 | 1430億5068万 | -7.84% |
| 02/25 | 15:30 「ミニリンメルト」及び「デスモプレシン製剤」の国内販売権移管に関するお知らせ |
| 02/25 | 2,762 | 2,799 | 2,735 | 2,763 | -3.46% | 123,300 | 1431億5430万 | -8.18% |
| 02/21 | 2,845 | 2,877 | 2,834 | 2,862 | +0.14% | 51,700 | 1482億8361万 | -5.23% |
| 02/20 | 2,851 | 2,880 | 2,851 | 2,858 | -0.03% | 43,500 | 1480億7636万 | -5.61% |
| 02/19 | 2,900 | 2,907 | 2,859 | 2,859 | +0.32% | 69,900 | 1481億2817万 | -5.83% |
| 02/18 | 2,889 | 2,896 | 2,845 | 2,850 | -2.33% | 57,300 | 1476億6187万 | -6.37% |
| 02/17 | 2,963 | 2,963 | 2,907 | 2,918 | -2.24% | 38,300 | 1511億8503万 | -4.48% |
| 02/14 | 2,951 | 2,991 | 2,950 | 2,985 | +0.64% | 52,900 | 1546億5638万 | -2.55% |
| 02/13 | 2,960 | 2,974 | 2,911 | 2,966 | -0.74% | 39,000 | 1536億7197万 | -3.29% |
| 02/12 | 3,040 | 3,040 | 2,965 | 2,988 | -2.03% | 60,000 | 1548億1182万 | -2.77% |
| 02/10 | 3,080 | 3,095 | 3,050 | 3,050 | -2.09% | 47,400 | 1580億2411万 | -0.81% |
| 02/07 | 3,095 | 3,115 | 3,070 | 3,115 | +1.14% | 33,900 | 1613億9184万 | +1.2% |
| 02/06 | 3,080 | 3,105 | 3,075 | 3,080 | +0.82% | 77,500 | 1595億7844万 | 0% |
| 02/05 | 3,065 | 3,100 | 3,045 | 3,055 | +0.99% | 102,300 | 1582億8317万 | -0.91% |
| 02/04 | 2,986 | 3,050 | 2,986 | 3,025 | +1.58% | 106,600 | 1567億2883万 | -1.98% |
| 02/03 | 10:00 2型糖尿病治療薬「マリゼブ」の販売移管に関するお知らせ |
| 02/03 | 2,985 | 3,030 | 2,947 | 2,978 | -4.7% | 146,300 | 1542億9370万 | -3.66% |
| 01/31 | 15:00 2020年3月期第3四半期決算短信〔日本基準〕(連結) |
| 01/31 | 15:00 2020年3月期第3四半期決算補足資料 |
| 01/31 | 3,085 | 3,160 | 3,085 | 3,125 | +1.3% | 66,200 | 1619億995万 | +0.9% |
| 01/30 | 3,085 | 3,125 | 3,080 | 3,085 | +0.16% | 59,400 | 1598億3750万 | -0.39% |
| 01/29 | 3,060 | 3,090 | 3,050 | 3,080 | +1.15% | 57,200 | 1595億7844万 | -0.61% |
| 01/28 | 3,030 | 3,065 | 3,010 | 3,045 | -0.16% | 64,600 | 1577億6505万 | -1.81% |
| 01/27 | 3,030 | 3,075 | 3,025 | 3,050 | -0.97% | 45,000 | 1580億2411万 | -1.8% |
| 01/24 | 3,105 | 3,110 | 3,055 | 3,080 | -0.96% | 39,200 | 1595億7844万 | -0.87% |
| 01/23 | 3,140 | 3,140 | 3,095 | 3,110 | -0.64% | 39,100 | 1611億3278万 | +0.1% |
| 01/22 | 3,095 | 3,150 | 3,095 | 3,130 | +1.79% | 48,100 | 1621億6900万 | +0.81% |
| 01/21 | 3,070 | 3,100 | 3,070 | 3,075 | -0.65% | 21,800 | 1593億1939万 | -0.87% |
| 01/20 | 3,055 | 3,105 | 3,050 | 3,095 | +1.81% | 32,300 | 1603億5561万 | -0.19% |
| 01/17 | 3,065 | 3,070 | 3,030 | 3,040 | -0.33% | 32,700 | 1575億600万 | -2% |
| 01/16 | 3,080 | 3,090 | 3,050 | 3,050 | -0.16% | 36,800 | 1580億2411万 | -1.64% |
| 01/15 | 3,095 | 3,095 | 3,030 | 3,055 | -0.65% | 38,900 | 1582億8317万 | -1.42% |
| 01/14 | 3,140 | 3,145 | 3,065 | 3,075 | -1.76% | 55,200 | 1593億1939万 | -0.74% |
| 01/10 | 3,100 | 3,145 | 3,100 | 3,130 | +0.48% | 38,900 | 1621億6900万 | +1.13% |
| 01/09 | 3,125 | 3,165 | 3,085 | 3,115 | +1.3% | 37,300 | 1613億9184万 | +0.74% |
| 01/08 | 3,050 | 3,100 | 3,025 | 3,075 | -1.13% | 70,100 | 1593億1939万 | -0.42% |
| 01/07 | 3,070 | 3,120 | 3,065 | 3,110 | +2.3% | 46,700 | 1611億3278万 | +0.84% |
| 01/06 | 3,050 | 3,065 | 3,030 | 3,040 | -2.56% | 57,500 | 1575億600万 | -1.3% |
| 2019 |
| 12/30 | 3,155 | 3,155 | 3,100 | 3,120 | -2.04% | 43,400 | 1616億5089万 | +1.46% |
| 12/27 | 3,165 | 3,210 | 3,165 | 3,185 | +0.95% | 45,800 | 1650億1862万 | +3.85% |
| 12/26 | 3,115 | 3,155 | 3,115 | 3,155 | +0.8% | 37,500 | 1634億6428万 | +3.27% |
| 12/25 | 3,155 | 3,155 | 3,130 | 3,130 | -0.48% | 36,300 | 1621億6900万 | +2.83% |
| 12/24 | 3,130 | 3,160 | 3,120 | 3,145 | +0.96% | 31,500 | 1629億4617万 | +3.66% |
| 12/23 | 3,150 | 3,155 | 3,115 | 3,115 | -0.95% | 48,100 | 1613億9184万 | +3.08% |
| 12/20 | 3,115 | 3,155 | 3,075 | 3,145 | +0.48% | 130,500 | 1629億4617万 | +4.35% |
| 12/19 | 3,120 | 3,155 | 3,100 | 3,130 | +0.32% | 35,200 | 1621億6900万 | +4.26% |
| 12/18 | 3,160 | 3,160 | 3,090 | 3,120 | -1.89% | 64,200 | 1616億5089万 | +4.35% |
| 12/17 | 3,130 | 3,195 | 3,115 | 3,180 | +3.25% | 64,600 | 1647億5956万 | +6.71% |
| 12/16 | 3,085 | 3,115 | 3,075 | 3,080 | +0.33% | 62,400 | 1595億7844万 | +3.7% |
| 12/13 | 3,100 | 3,110 | 3,070 | 3,070 | +0.66% | 115,100 | 1590億6033万 | +3.58% |
| 12/12 | 3,085 | 3,095 | 3,050 | 3,050 | -0.81% | 57,100 | 1580億2411万 | +3.11% |
| 12/11 | 3,060 | 3,130 | 3,060 | 3,075 | +1.49% | 72,900 | 1593億1939万 | +4.2% |
| 12/10 | 3,055 | 3,105 | 3,020 | 3,030 | -3.04% | 118,500 | 1569億8789万 | +3.1% |
| 12/09 | 17:00 GnRHアンタゴニスト「リンザゴリクス(KLH-2109)」の海外における子宮筋腫を対象とした第3相臨床試験(PRIMROSE2試験)の中間解析結果について |
| 12/09 | 3,030 | 3,140 | 3,010 | 3,125 | +3.82% | 92,600 | 1619億995万 | +6.62% |
| 12/06 | 3,005 | 3,020 | 2,971 | 3,010 | +0.17% | 51,900 | 1559億5166万 | +3.19% |
| 12/05 | 3,040 | 3,045 | 3,000 | 3,005 | -0.66% | 36,800 | 1556億9261万 | +3.3% |
| 12/04 | 2,969 | 3,040 | 2,969 | 3,025 | +0.5% | 64,800 | 1567億2883万 | +4.27% |
| 12/03 | 3,035 | 3,035 | 2,982 | 3,010 | -1.31% | 38,600 | 1559億5166万 | +4.08% |
| 12/02 | 3,025 | 3,075 | 3,025 | 3,050 | +1.33% | 61,200 | 1580億2411万 | +5.76% |
| 11/29 | 3,015 | 3,030 | 2,997 | 3,010 | +0.94% | 71,300 | 1559億5166万 | +4.73% |
| 11/28 | 3,020 | 3,020 | 2,944 | 2,982 | -0.93% | 93,700 | 1545億95万 | +4.12% |
| 11/27 | 3,005 | 3,075 | 2,989 | 3,010 | +3.19% | 103,000 | 1559億5166万 | +5.43% |
| 11/26 | 16:00 補体C5a受容体阻害剤「アバコパン(CCX168)」の国際共同第3相臨床試験(ADVOCATE試験)の結果について |
| 11/26 | 2,950 | 2,967 | 2,915 | 2,917 | -0.1% | 72,100 | 1511億3322万 | +2.6% |
| 11/25 | 2,908 | 2,923 | 2,888 | 2,920 | +1.25% | 26,000 | 1512億8866万 | +3.03% |
| 11/22 | 2,889 | 2,912 | 2,884 | 2,884 | +0.21% | 34,000 | 1494億2345万 | +2.02% |
| 11/21 | 2,903 | 2,915 | 2,835 | 2,878 | -0.28% | 42,500 | 1491億1259万 | +1.98% |
| 11/20 | 2,869 | 2,890 | 2,841 | 2,886 | +1.3% | 39,900 | 1495億2707万 | +2.49% |
| 11/19 | 2,873 | 2,887 | 2,836 | 2,849 | -1.66% | 38,100 | 1476億1006万 | +1.5% |
| 11/18 | 2,861 | 2,897 | 2,848 | 2,897 | +1.68% | 43,600 | 1500億9700万 | +3.46% |
| 11/15 | 2,848 | 2,872 | 2,834 | 2,849 | +0.53% | 46,800 | 1476億1006万 | +2.11% |
| 11/14 | 2,890 | 2,890 | 2,824 | 2,834 | -1.77% | 37,500 | 1468億3289万 | +1.87% |
| 11/13 | 2,937 | 2,957 | 2,883 | 2,885 | -1.43% | 68,300 | 1494億7526万 | +4.04% |
| 11/12 | 2,952 | 2,952 | 2,908 | 2,927 | -0.17% | 46,700 | 1516億5133万 | +6.01% |
| 11/11 | 2,937 | 2,966 | 2,911 | 2,932 | +1% | 71,500 | 1519億1039万 | +6.73% |
| 11/08 | 2,903 | 2,927 | 2,880 | 2,903 | +1.15% | 87,100 | 1504億787万 | +6.07% |
| 11/07 | 2,735 | 2,878 | 2,735 | 2,870 | +2.65% | 124,400 | 1486億9810万 | +5.28% |
| 11/06 | 15:00 2020年3月期第2四半期決算補足資料 |
| 11/06 | 15:00 2020年3月期第2四半期決算短信〔日本基準〕(連結) |
| 11/06 | 2,824 | 2,831 | 2,773 | 2,796 | -1.1% | 63,000 | 1448億6407万 | +2.98% |
| 11/05 | 2,795 | 2,837 | 2,765 | 2,827 | +2.24% | 108,600 | 1464億7021万 | +4.43% |
| 11/01 | 2,791 | 2,791 | 2,747 | 2,765 | -1.5% | 53,300 | 1432億5792万 | +2.41% |
| 10/31 | 2,812 | 2,826 | 2,791 | 2,807 | -0.07% | 70,200 | 1454億3399万 | +4.16% |
| 10/30 | 2,809 | 2,810 | 2,777 | 2,809 | 0% | 95,000 | 1455億3761万 | +4.54% |
| 10/29 | 2,827 | 2,836 | 2,806 | 2,809 | +0.18% | 44,700 | 1455億3761万 | +4.89% |
| 10/28 | 2,826 | 2,828 | 2,789 | 2,804 | +0.07% | 51,200 | 1452億7856万 | +5.06% |
| 10/25 | 2,781 | 2,807 | 2,772 | 2,802 | +1.48% | 76,900 | 1451億7494万 | +5.34% |
| 10/24 | 2,799 | 2,799 | 2,753 | 2,761 | +0.11% | 49,200 | 1430億5068万 | +4.11% |
| 10/23 | 2,722 | 2,763 | 2,690 | 2,758 | +2.38% | 61,100 | 1428億9524万 | +4.23% |
| 10/21 | 2,721 | 2,728 | 2,687 | 2,694 | -0.7% | 21,900 | 1395億7933万 | +2.08% |
| 10/18 | 2,728 | 2,762 | 2,706 | 2,713 | -0.55% | 46,100 | 1405億6374万 | +2.96% |
| 10/17 | 2,777 | 2,777 | 2,722 | 2,728 | -1.02% | 68,500 | 1413億4091万 | +3.84% |
